The radiobiology of conventional radiotherapy and its application to radionuclide therapy.

The linear-quadratic (LQ) model of radiobiological effect is well established in conventional, i.e., external beam, radiotherapy. Because the model is derived from sound biophysical principles, it is also emerging as the standard formalism for assessing biological responses for the whole range of radiotherapy treatments. A central feature of LQ methodology is the quantity known as the biologically effective dose (BED), which may be used to quantify the radiobiological impact of a treatment on both tumors and normal tissues. The BEDs commonly associated with conventional therapy may thus be compared to those expected from novel radiotherapy treatments, such as targeted radionuclide therapy. This approach also provides a mechanism for designing targeted treatments which are therapeutically equivalent to external beam treatments. In this paper the LQ methodology is outlined and worked examples are provided which demonstrate the tentative link between targeted radiotherapy doses and those used in conventional radiotherapy. The incorporation of an allowance for relative biological effectiveness (RBE) effects is also discussed. The complexity of the subject and the potentially large number of variables does place a restriction on overall predictive accuracy and the necessary caveats are outlined.

[1]  S. Goddu,et al.  Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  R G Dale,et al.  Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.

[3]  H D Thames,et al.  An 'incomplete-repair' model for survival after fractionated and continuous irradiations. , 1985, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[4]  J. O’Donoghue Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. , 2004, Cancer biotherapy & radiopharmaceuticals.

[5]  R G Dale,et al.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. , 1985, The British journal of radiology.

[6]  L. Gerweck,et al.  Relative biological effectiveness of proton beams in clinical therapy. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  R. Dale,et al.  A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd , 2001, Physics in medicine and biology.

[8]  G. Barendsen,et al.  Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. , 1982, International journal of radiation oncology, biology, physics.

[9]  Harald Paganetti,et al.  Relative biological effectiveness (RBE) values for proton beam therapy. , 2002, International journal of radiation oncology, biology, physics.

[10]  J. Fowler The linear-quadratic formula and progress in fractionated radiotherapy. , 1989, The British journal of radiology.

[11]  L. Verhey,et al.  Relative biological effectiveness of modulated proton beams in various murine tissues. , 1984, International journal of radiation oncology, biology, physics.

[12]  H. Thierens,et al.  In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  R. Dale,et al.  Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. , 2004, Cancer biotherapy & radiopharmaceuticals.